Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Do I understand this correctly?

There is 6.7 mil. in cash and 12.5mil. in marketable securities (ARS). That gives us 19.2 mil. on our balance sheet. The ARS situation is getting better overall and we should be able to get rid of them soon. IMHO, this is by far the easiet report to read that I have seen in the last 9 years. I commend RG for making things more transparent for us. I have a feeling that we are going to hear a lot more on the M&A front within the next few days. I also have this "gut feeling" that we will be hearing about some new BOD members as I think that it will look better if we have the correct # when RG and IBIS start pitching our tune to investors. So far, I like everything that I have read in the report. We are making great progress. GL, ads

Share
New Message
Please login to post a reply